J.P. Morgan Notebook Day 3: Lilly's CGRP Prospects, Juno On Track, Color From Alnylam's Greene, Shire's New CMO

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: Lilly CEO on CGRP reimbursement jitters, Alnylam president on Sanofi deal terms, Juno stakes BCMA myeloma claim, Shire's new CMO.

San Francisco, CA with trolly car

Eli Lilly & Co. CEO David Ricks attempted to allay investor concern during the J.P. Morgan Healthcare Conference about the likelihood of favorable reimbursement for the company’s biologic galcanezumab, which is under review at the US FDA and is in a tight race with rivals to be the first calcitonin gene-related peptide (CGRP) inhibitor approved for the prevention of migraine headaches.

Amgen Inc. and its partner Novartis AG are talking to payers about reimbursement schemes that provide payment only...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip